Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Berenson JR, et al. Among authors: nassir y. Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129. Epub 2012 Nov 15. Br J Haematol. 2013. PMID: 23150919 Free article. Clinical Trial.
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R. Berenson JR, et al. Among authors: nassir y. Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8. Ann Hematol. 2008. PMID: 18463870 Clinical Trial.
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, Swift RA. Berenson JR, et al. Among authors: nassir y. Eur J Haematol. 2009 Jun;82(6):433-9. doi: 10.1111/j.1600-0609.2009.01244.x. Epub 2009 Feb 17. Eur J Haematol. 2009. PMID: 19226361 Clinical Trial.
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Berenson JR, Yellin O, Chen CS, Patel R, Bessudo A, Boccia RV, Yang HH, Vescio R, Yung E, Mapes R, Eades B, Hilger JD, Wirtschafter E, Hilger J, Nassir Y, Swift RA. Berenson JR, et al. Among authors: nassir y. Br J Haematol. 2011 Dec;155(5):580-7. doi: 10.1111/j.1365-2141.2011.08884.x. Epub 2011 Sep 26. Br J Haematol. 2011. PMID: 21950583 Free article. Clinical Trial.
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Cohen A, Spektor TM, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Maluso T, Swift RA, Vescio R, Berenson JR. Cohen A, et al. Among authors: nassir y. Br J Haematol. 2018 Jan;180(1):60-70. doi: 10.1111/bjh.14992. Epub 2017 Nov 21. Br J Haematol. 2018. PMID: 29164606 Free article. Clinical Trial.
24 results